KEYLearning Hub
Optimise treatment outcome for your
1L aRCC patients treated with
KEYTRUDA® (pembrolizumab) plus
KISPLYX® (lenvatinib)
Patient Case Studies
Patient Case Studies
KEYTRUDA® (pembrolizumab) Prescribing Information for Great Britain & Northern Ireland [External links]
KISPLYX® (lenvatinib) Prescribing information for Great Britain & Northern Ireland [External link]
Welcome to the advanced RCC KEYLearning Hub, learn from your fellow clinicians below as they describe their experiences of managing patients being treated with KEYTRUDA in combination with KISPLYX.
KEYTRUDA, in combination with KISPLYX, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.1
Please refer to the individual product SmPCs before prescribing.
First-line treatment of advanced RCC patient with multiple metastases
Case study summary
Dr Ricky Frazer, Consultant Medical Oncologist at the Velindre Cancer Centre in Cardiff presents a case study of a 57 year old male with advanced renal cell carcinoma, treated with KEYTRUDA in combination with KISPLYX. This patient was diagnosed with multiple metastases (lung mets and large bone mets) and was classified as IMDC intermediate risk.
Dr Ricky Frazer, describes his treatment decision making, management of adverse events and the patient’s treatment outcome.
This content is intended to be viewed on laptop/desktop only, for optimal view please watch the video in full-screen using the button in the bottom right.
KEYTRUDA® (pembrolizumab) Prescribing Information for Great Britain & Northern Ireland [External links]
KISPLYX® (lenvatinib) Prescribing information for Great Britain & Northern Ireland [External link]
Filmed: May 2023 | Length: 10:31
First-line treatment of advanced RCC patient with sarcomatoid features and bone metastases
Case study summary
Dr John McGrane, Consultant Clinical Oncologist at the Royal Cornwall Hospitals NHS Trust in Truro presents a case study of a 62 year old male with advanced renal cell carcinoma, treated with KEYTRUDA in combination with KISPLYX. This patient was diagnosed with sarcomatoid features and bone metastases and was classified as IMDC intermediate risk.
Dr John McGrane, describes his treatment decision making, management of adverse events and the patient’s treatment outcome.
This content is intended to be viewed on laptop/desktop only, for optimal view please watch the video in full-screen using the button in the bottom right.
KEYTRUDA® (pembrolizumab) Prescribing Information for Great Britain & Northern Ireland [External links]
KISPLYX® (lenvatinib) Prescribing information for Great Britain & Northern Ireland [External link]
Filmed: June 2023 | Length: 11:22
First-line treatment of advanced RCC patient with spinal metastases, pulmonary and adrenal nodules
Case study summary
Dr Richard Griffiths, Consultant Medical Oncologist at the Clatterbridge Cancer Centre NHS Foundation Trust presents a case study of a 61 year old female with advanced renal cell carcinoma, treated with KEYTRUDA in combination with KISPLYX. This patient was diagnosed with spinal metastases, pulmonary and adrenal nodules and was classified as IMDC intermediate risk.
Dr Richard Griffiths, describes his treatment decision making, management of adverse events and the patient’s treatment outcome.
This content is intended to be viewed on laptop/desktop only, for optimal view please watch the video in full-screen using the button in the bottom right.
KEYTRUDA® (pembrolizumab) Prescribing Information for Great Britain & Northern Ireland [External links]
KISPLYX® (lenvatinib) Prescribing information for Great Britain & Northern Ireland [External link]
Filmed: June 2023 | Length: 09:23
Reference
- KEYTRUDA Summary of Product Characteristics.
Supporting documentation
KEYTRUDA Prescribing Information for Great Britain & Northern Ireland
KISPLYX Prescribing information for Great Britain & Northern Ireland
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
